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Introduction {#sec1}
============

The fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS) is caused by loss of motoneurons (MNs) in the spinal cord and brain, leading to progressive muscle atrophy. Both sporadic ALS (sALS) and familial ALS (fALS) have been linked to a number of genes, including *SOD1*, *C9ORF72*, *TDP-43*, *TAF15*, and *FUS/TLS* (*FUS*) ([@bib41]). The *FUS* gene encodes for an RNA-binding protein involved in RNA biogenesis and maturation ([@bib31]). Wild-type (WT) FUS is mainly localized in the nucleus, and a hallmark of *FUS* ALS patients is the presence of cytoplasmic inclusions containing mutated protein in the brain and spinal cord ([@bib29], [@bib45]). Many ALS-associated *FUS* mutations disrupt the function of the C-terminal nuclear localization signal (NLS). Therefore, defects in nuclear import, leading to aberrant cytoplasmic localization of FUS, have been proposed as the initial step in ALS pathogenesis ([@bib7], [@bib16]). Recent analyses in murine models suggest that loss of FUS function may not be sufficient to induce MN degeneration ([@bib25], [@bib43]), and both loss of a nuclear function and gain of a toxic function in the cytoplasm have been proposed as contributing pathological mechanisms in *FUS* ALS ([@bib34]).

*FUS* mutations are expected to exert a major change in the transcriptome. However, this has not been directly addressed in human MNs so far. Human induced pluripotent stem cells (iPSCs) represent a useful system to model ALS, as they can be differentiated into disease-relevant cell types ([@bib42]). iPSCs carrying ALS mutations can be generated by reprogramming from patients ([@bib9]) or by gene-editing techniques, producing lines that differ only for the specific mutation ([@bib26], [@bib32]). Comparison of gene-edited mutant lines with their otherwise isogenic WT counterparts allows to assign any observed phenotypic difference to the ALS mutation, avoiding any bias due to different genetic backgrounds of non-isogenic mutants and controls.

Recent evidence suggests that microRNAs (miRNAs) might play a role in MN diseases, such as ALS and spinal muscular atrophy (SMA) ([@bib30]). Conditional loss of the processing enzyme Dicer in postnatal MNs causes an SMA-like phenotype in mice ([@bib20]), suggesting that, collectively, miRNAs could be required for MN survival. Global downregulation of miRNAs was observed in MNs of sporadic ALS spinal cords isolated by laser-capture microdissection ([@bib17]), and a protective role for individual miRNAs, such as miR-218 and miR-375, has been shown in MNs ([@bib4], [@bib8]). Previous work from our lab and others has shown that proteins genetically linked to ALS play a role in miRNA biogenesis. FUS stimulates miRNA processing by facilitating the recruitment of the enzyme Drosha on miRNA genes ([@bib37]), and TDP-43 regulates miRNA biogenesis at multiple levels ([@bib11], [@bib15], [@bib24]). Moreover, overexpression of SOD1, TDP-43, or FUS proteins, either WT or carrying ALS mutations, impaired miRNA processing in the cytoplasm by inducing cellular stress ([@bib17]). As most of the studies on the contribution of ALS-linked factors to miRNA biogenesis come from cell lines or non-MN cells, it is currently unknown which miRNAs could be affected by ALS mutations in MNs.

Here we took advantage of mutant FUS^P525L^ and isogenic control iPSCs to generate and isolate pure human MNs, which were used for whole-transcriptome analysis by RNA sequencing (RNA-seq). We identified both long and short RNA species significantly altered in *FUS* mutant MNs. Changes in the transcriptome point to pathways previously associated to neurodegenerative diseases, such as those related to cell adhesion. Among differentially expressed miRNAs we focused on miR-375. Levels of miR-375 were decreased in mutant MNs, in which we observed an increase of a subset of its targets, such as p53 and the neural RNA-binding protein ELAVL4. We propose a pathological mechanism in which an impairment of miRNAs production, downstream of *FUS* mutations, would alter RNA metabolism and increase MN vulnerability via aberrant upregulation of pro-apoptotic targets.

Results {#sec2}
=======

Differentiation and Isolation of iPSC-Derived MNs {#sec2.1}
-------------------------------------------------

We have recently reported the generation of iPSC lines devoid of mutations in the *FUS* gene (hereafter FUS^WT^) or carrying the severe P525L ALS-related mutation introduced by gene editing in both *FUS* alleles (hereafter FUS^P525L^) ([@bib32]). We stably modified these lines by inserting a *Hb9*:GFP reporter into the *AAVS1* locus ([@bib47]) ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). To improve time and efficiency of MN generation from iPSCs, we took advantage of an optimized protocol based on neural induction and patterning of differentiating cells in adhesion conditions ([Figure 1](#fig1){ref-type="fig"}A). Using this protocol we consistently obtained MN progenitors in a 12 day time frame. A time course analysis of marker expression in differentiating FUS^WT^ cells is shown in [Figure 1](#fig1){ref-type="fig"}B. By day 6, cells lose the pluripotency marker *NANOG*. Around this time point we detected a peak of expression for the neural progenitor gene *PAX6*, followed by a raise of pan-neuronal (*TUJ1*) and MN (*ISL1*) markers at day 9. The late MN gene *CHAT* was expressed at day 9, with a further increase until day 12. Levels of the MN progenitor marker *HB9* peaked around day 9 and decreased at later time points. The mixed population of differentiated cells at day 12 was highly enriched of *ISL1/2*-positive neurons ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Live cell imaging and flow cytometry analysis indicated that 30%--40% of cells were GFP-positive at this time point ([Figures 1](#fig1){ref-type="fig"}C and 1D). Notably, expression of the reporter was detected only in retinoic acid and smoothened agonist (SAG)-treated cells, which induce a ventral spinal cord character, suggesting that the exogenous *Hb9* promoter was correctly turned on in the MN lineage ([Figure 1](#fig1){ref-type="fig"}E). We further validated the reporter system by gene expression analysis in distinct cell populations isolated using cell sorting ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Next-generation sequencing (RNA-seq) was performed on total RNA from GFP-positive and -negative cells collected after sorting. Cluster analysis based on gene expression data correctly separated the samples into GFP-positive and -negative ones ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). GFP-positive samples had a similar expression profile, while GFP-negative ones were more dissimilar. A total of 1,631 genes were differentially expressed between GFP-positive and -negative cells, most of them having higher expression levels in GFP-negative samples ([Figure S1](#mmc1){ref-type="supplementary-material"}G; [Table S1](#mmc2){ref-type="supplementary-material"}). As shown in [Figure 1](#fig1){ref-type="fig"}F, levels of MN markers (in green) were higher in GFP-positive samples, with the exception of *LHX1*. Notably, the *HB9* transcript was not significantly enriched in GFP-positive samples. This apparent inconsistency can be explained by the narrow window of time of HB9 expression: by the time point in which GFP protein reaches its maximum accumulation (day 12; [Figure 1](#fig1){ref-type="fig"}D) the endogenous *HB9* mRNA is already downregulated ([Figure 1](#fig1){ref-type="fig"}B). Compared with GFP-positive cells, GFP-negative populations probably contained a fraction of MN progenitors at earlier stages, expressing high levels of *HB9*. As expected, ALS-related genes *SOD1*, *C9ORF72*, *FUS*, and *TARDBP* were not enriched in GFP-positive cells. Experimental validation of selected markers by real-time qPCR confirmed the RNA-seq results ([Figure 1](#fig1){ref-type="fig"}G). Purified GFP-positive cells were re-plated on laminin-coated dishes and upon further culturing acquired a neuronal morphology ([Figure S1](#mmc1){ref-type="supplementary-material"}H). Immunostaining analysis indicated that sorted GFP-positive cells were highly enriched for *ISL1/2*-positive MNs ([Figure 1](#fig1){ref-type="fig"}H).Figure 1MN Differentiation Protocol and *Hb9*:GFP Reporter(A) Schematic representation of the differentiation protocol.(B) Real-time qRT-PCR marker expression analysis. For each marker the time point with the highest expression has been used as the calibrator sample.(C) Live cell imaging of GFP expression in differentiated cells at day 12. Scale bar, 80 μm.(D) Schematic representation of flow cytometry analysis of the fraction of GFP-positive cells during differentiation.(E) Cells were differentiated as in (A) in the presence (right) or in the absence (left) of retinoic acid and SAG, and analyzed by fluorescence-activated cell sorting (FACS) at day 12.(F) Heatmap representing expression levels of selected genes in sorted GFP-positive and -negative cells (two independent experiments). Plotted values correspond to mean-centered log2-transformed reads per kilobase of transcript per million mapped reads (RPKM) values. MN markers are indicated in green, ALS genes in red, and housekeeping controls in black.(G) Real-time qRT-PCR analysis of the expression of the indicated genes in unsorted cells (black bars) and GFP-negative (gray bars) and GFP-positive (green bars) cells isolated by FACS (day 12). For each gene the unsorted cells sample has been used as calibrator. Histogram bars represent the average of a technical replicate (n = 3) and error bars indicate the SD.(H) Immunostaining analysis of sorted MNs (day 12 + 3) with an anti-ISL1/2 antibody (green). Nuclei were stained with DAPI (blue). Upper panels show single channels. Lower panels show merged channels and overlay with the phase contrast image. Scale bar, 40 μm. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Taken together, the combination of a short and efficient differentiation protocol and the stable insertion of the *Hb9*:GFP reporter allowed the effective isolation of a large number of purified, iPSC-derived, MNs.

Transcriptome Profiling in FUS WT and Mutant Human MNs {#sec2.2}
------------------------------------------------------

We have previously shown that ALS mutations in *FUS* do not impair differentiation ([@bib32], [@bib33]). This observation was confirmed in MNs generated with the improved protocol described in [Figure 1](#fig1){ref-type="fig"} from FUS^WT^ and FUS^P525L^ iPSCs. The fraction of GFP-positive cells was consistently comparable over six independent experiments ([Figures 2](#fig2){ref-type="fig"}A and 2B). Moreover, GFP-positive cells with a FUS^WT^ or FUS^P525L^ background showed comparable levels of expression of MN markers ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Notably, in the *Hb9*:GFP FUS^P525L^ line both the mutation and the reporter system have been introduced by gene editing. Therefore, besides the FUS^P525L^ mutation, iPSC lines used for subsequent experiments were isogenic.Figure 2RNA-Seq Analysis of FUS^WT^ and FUS^P525L^ iPSC-Derived MNs(A) Representative FACS plots of FUS^WT^ and FUS^P525L^ cells at day 12. As a negative control, FUS^WT^ cells were differentiated in the absence of retinoic acid and SAG (left panel).(B) Schematic representation of flow cytometry analysis (day 12). Histogram bars represent the average of six independent experiments and error bars indicate the SD (Student\'s t test; unpaired; two tails; n.s., p \> 0.05).(C) Heatmap representing RNA-seq-derived expression levels of differentially expressed genes at day 12 + 7 (three independent experiments). Plotted values correspond to mean-centered log2-transformed RPKM values.(D) Validation of selected genes by real-time qRT-PCR in MNs at day 12 + 7. Expression levels in FUS^P525L^, FUS^P525L^\#2, and FUS^P525L^(ht) are shown as relative to their respective isogenic FUS^WT^ controls, set to a value of 1. Histogram bars represent the average of at least three independent experiments and error bars indicate the SD (Student\'s t test; paired; two tails; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; n.s., p \> 0.05). See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

We took advantage of our iPSC system to systematically analyze the consequences of the FUS^P525L^ mutation on the transcriptome in pure populations of *in-vitro*-derived human MNs. GFP-positive FUS^WT^ and FUS^P525L^ iPSCs were sorted at day 12 of differentiation and further cultured on laminin-coated dishes for an additional 7 days (day 12 + 7). Total RNA from three independent differentiation experiments was collected and analyzed by RNA-seq. Gene expression-based cluster analysis resulted in the segregation of samples into two distinct groups based on their *FUS* genotype ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Out of 14,289 genes expressed in human MNs, 267 genes were upregulated and 244 downregulated in a consistent manner in FUS^P525L^ compared with FUS^WT^ (false discovery rate \[FDR\] \< 0.05) ([Table S1](#mmc2){ref-type="supplementary-material"}). The gene expression heatmap of differentially expressed genes is shown in [Figure 2](#fig2){ref-type="fig"}C. RNA-seq results were validated by real-time qPCR in at least three additional independent samples. [Figure 2](#fig2){ref-type="fig"}D shows validation of four representative genes among those downregulated (*SCL17A8*, *NXPH2*, *CRIM1*, and *GRIN2A*) and upregulated (*TP53I3*, *CDH7*, *NNAT*, and *TSPYL5*). Expression of the *FUS* transcript itself, as well as the mRNAs of other major ALS-related genes, was not significantly altered in *FUS* mutant MNs ([Figure S2](#mmc1){ref-type="supplementary-material"}D).

We confirmed these results in an independent *FUS* WT and mutant isogenic pair. A second FUS^P525L^ iPSC line (hereafter FUS^P525L^\#2), generated as previously described ([@bib32]), and its parental FUS^WT^ iPSC line (hereafter FUS^WT^\#2) were modified by inserting the *Hb9*:GFP reporter into the *AAVS1* locus ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D). FUS^WT^\#2 and FUS^P525L^\#2 were then differentiated, sorted, and collected at day 12 + 7 for RNA analysis. All genes analyzed in the original isogenic pair resulted consistently altered in MNs obtained from these new iPSC lines ([Figure 2](#fig2){ref-type="fig"}D).

A subset of these genes was also affected in MNs obtained from a *Hb9*:GFP-modified heterozygous FUS^P525L^ iPSC line, hereafter FUS^P525L^(ht) ([@bib32]) ([Figure 2](#fig2){ref-type="fig"}D).

Functional Consequences of the FUS^P525L^ Mutation in Human MNs {#sec2.3}
---------------------------------------------------------------

We next assessed whether the change in the transcriptome detected in *FUS* mutant cells might be informative of pathways potentially involved in ALS MN degeneration. Gene ontology (GO) term enrichment analysis with the FIDEA tool ([@bib14]) highlighted relevant categories that cooperate in pathways and distinct molecular functions. In particular, we noticed a striking enrichment for categories related to cell adhesion in genes differentially expressed in FUS^P525L^ MNs ([Figure 3](#fig3){ref-type="fig"}A). Notably, "cell adhesion" is one of the categories consistently enriched in multiple studies focusing on FUS-bound transcripts and splice targets in mouse and human neurons ([@bib39]). GO term enrichment analysis of differentially expressed genes in laser-captured MNs from postmortem sporadic ALS patients also indicated "cell adhesion" ([@bib6]). Moreover, functional enrichment analysis for genome-wide association studies involving several neurological diseases (including ALS) showed significant values for the "cell-cell adhesion" GO category ([@bib19]). This category was also enriched in the analysis of differentially expressed genes in ALS fibroblasts carrying the *C9ORF72* mutation ([@bib28]). Cell adhesion-related categories were enriched also when upregulated and downregulated genes were analyzed separately ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Interestingly, the Kyoto Enrichment of Genes and Genomes pathway "Neuroactive ligand-receptor interaction" was specifically enriched by the downregulated genes. Previous work found this pathway enriched in RNA profiling from *C9ORF72* mutant fibroblasts ([@bib28]) and linked to neurological diseases such as Parkinson\'s disease ([@bib27]).Figure 3Bioinformatics Analysis of Differentially Expressed Genes in FUS^WT^ and FUS^P525L^ MNs(A) Word cloud generated by FIDEA representing GO biological process terms enriched in the list of genes that are differentially expressed between FUS^WT^ and FUS^P525L^ MNs. The functional categories are represented with a character size proportional to the statistical significance of their enrichment.(B) The histogram shows the fold enrichment of FUS binding sites, identified by re-analysis of data from [@bib31], in different regions of pre-mRNAs, after normalization to average region size.(C) Fraction of FUS bound protein-coding genes, which are also differentially expressed genes in FUS mutant MNs. A gene was considered bound if a FUS HITS-CLIP peak was found within its body; the analysis was repeated focusing only on specific pre-mRNA regions (Fisher\'s exact test; ^∗^p \< 0.05; ^∗∗∗^p \< 0.001).(D) Validation of selected FUS-bound genes in MNs at day 12 + 7 by real-time qRT-PCR. Expression levels in FUS^P525L^, FUS^P525L^\#2, and FUS^P525L^(ht) are shown as relative to their respective isogenic FUS^WT^ controls, set to a value of 1. Histogram bars represent the average of at least three independent experiments and error bars indicate the SD (Student\'s t test; paired; two tails; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; n.s., p \> 0.05).(E) Venn diagram showing the overlap between differentially expressed genes in the present work and in a FUS mutant mouse ([@bib43]). See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Seeking for ALS signature in *FUS* mutant MNs, we crossed our RNA-seq data with a recently published dataset from laser-captured MNs fom sALS patients ([@bib6], [@bib23]). In these works, the authors found 2,346 upregulated and 955 downregulated genes in sALS patients. The variation of upregulated genes was more robust, since more stringent selection criteria had lower impact on their abundance. These two lists of genes were employed as two distinct gene sets in the context of a gene set enrichment analysis to evaluate whether they were over-represented in the set of genes deregulated upon *FUS* mutation. Notably, the set of genes downregulated in sALS patients was enriched among those downregulated in FUS^P525L^ (FDR = 0.151), and the set of genes upregulated in sALS patients was significantly enriched among those upregulated in FUS^P525L^ (FDR = 0.009) ([Figure S4](#mmc1){ref-type="supplementary-material"}B). These results suggest a common signature in gene expression between *in-vitro*-derived FUS^P525L^ MNs and sALS MNs. As suggested by FDR values, this tendency is stronger for the upregulated genes, consistent with the robustness of their deregulation in sALS patients.

We next investigated whether there is any relationship between differential gene expression and direct FUS binding in mutant MNs. The FUS interactome has never been characterized in purified human MNs; however, FUS CLIP-seq (crosslinking and immunoprecipitation, followed by high-throughput sequencing) data from human brain cortex are available ([@bib31]). We re-analyzed this dataset and evaluated the position of FUS binding clusters relative to the different regions of the pre-mRNAs, which are expressed in our MNs. FUS binding was enriched in the exonic regions of protein-coding genes, and in particular in the 3′ UTR, when compared with sequences located more (distal introns) or less (proximal introns) than 500 bp from the nearest exon-intron junction ([Figure 3](#fig3){ref-type="fig"}B). FUS-bound genes were classified as differentially expressed or not in FUS^P525L^ MNs, and individual mRNA regions were analyzed separately. A significantly higher percentage of genes modulated in FUS mutant MNs was directly bound by FUS in the distal intron and 3′ UTR ([Figure 3](#fig3){ref-type="fig"}C). When the same analysis was repeated with the TDP-43-bound genes dataset ([@bib44]), we did not observe a significant enrichment for the 3′ UTR set ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Taken together, these results suggest that mRNAs bound by FUS in the 3′ UTR might be more susceptible to changes in FUS activity due to ALS mutations. We validated differential expression of selected FUS-bound mRNAs in mutant MNs (*TAF7*, *TAF15*, *GRIN2A*, *PCDH10*, and *CRIM1*) ([Figures 2](#fig2){ref-type="fig"}D and [3](#fig3){ref-type="fig"}D).

To assess whether the changes in gene expression downstream of *FUS* ALS mutations are consistent with an animal model exhibiting ALS features, we crossed our data with the transcriptome profiling of a recently described mouse carrying targeted deletion of the PY-NLS (Fus^ΔNLS/ΔNLS^) ([@bib43]). This mutation severely impairs the nuclear localization of FUS, mimicking the human P525L mutation and other truncations of the protein C-terminal. Among differentially expressed genes, 17 were downregulated and 8 were upregulated in both mutant mouse brain and human MNs ([Figures 3](#fig3){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}D). The overlap was statistically significant both for upregulated and downregulated gene lists (p value for hypergeometric test \<0.05). Interestingly, mRNA levels of *TAF15*, a *FUS* family member mutated in a subset of fALS patients ([@bib13]), were significantly increased in both mouse ([@bib43]) and human ([Figure 3](#fig3){ref-type="fig"}D). *TAF15* was among the transcripts directly bound by FUS ([@bib31]). These findings suggest that a possible crosstalk between *FUS* and *TAF15*, hypothesized in murine models, might be conserved in human.

FUS^P525L^ Mutation Impairs miR-375 Biogenesis in MNs by a Loss-of-Function Mechanism {#sec2.4}
-------------------------------------------------------------------------------------

Previous studies in cell lines have hypothesized a link between *FUS* mutations and the impairment of miRNA function ([@bib17], [@bib37]), but this was never directly investigated in human MNs. We performed miRNA profiling by small RNA sequencing (small RNA-seq) in FUS^WT^ and FUS^P525L^ MNs. Based on miRNA expression levels, samples could be clustered according to their *FUS* genotype ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C). Of the 573 miRNAs expressed in human MNs (day 12 + 7), 21 resulted downregulated and 11 upregulated in FUS^P525L^ mutant cells (FDR \< 0.05) ([Figure S5](#mmc1){ref-type="supplementary-material"}D; [Table S1](#mmc2){ref-type="supplementary-material"}). We also analyzed to which extent the change in the miRNome is maintained at different time points. TaqMan array cards and small RNA-seq identified miR-375 and miR-484 as differentially expressed miRNAs at both day 12 and day 12 + 7 ([Figure 4](#fig4){ref-type="fig"}A; [Table S2](#mmc1){ref-type="supplementary-material"}). These and other selected candidates were analyzed by real-time qRT-PCR in FUS^P525L^, FUS^P525L^\#2, and FUS^P525L^(ht) MNs, and their isogenic WT controls ([Figures 4](#fig4){ref-type="fig"}B, [S5](#mmc1){ref-type="supplementary-material"}E, and S5F). Among them, miR-375 was consistently downregulated in both homozygous *FUS* mutant lines over at least four independent experiments ([Figure 4](#fig4){ref-type="fig"}B).Figure 4miR-375 Is Downregulated in FUS Mutant MNs(A) Venn diagram showing the relations between differentially expressed miRNAs at different time points of MN maturation, as resulting from TaqMan array cards analysis in FUS^WT^ and FUS^P525L^ iPSC-derived MNs at day 12 and 12 + 7, and small RNA-seq at day 12 + 7 (p \< 0.05).(B) Validation of selected miRNAs by real-time qRT-PCR in MNs at day 12 + 7. Expression levels in FUS^P525L^ and FUS^P525L^\#2 are shown as relative to their respective isogenic FUS^WT^ controls, set to a value of 1. Histogram bars represent the average of at least four independent experiments and error bars indicate the SD (Student\'s t test; paired; two tails; ^∗^p \< 0.05; ^∗∗∗^p \< 0.001; n.s., p \> 0.05).(C) Real-time qRT-PCR analysis of the indicated miRNAs in FUS^WT^ undifferentiated iPSCs and MNs (day 12 of differentiation, unsorted). miR-302a and miR-367 are pluripotency miRNAs; miR-218 is an MN-enriched miRNA. For each miRNA, the sample with the highest expression has been used as the calibrator. Histogram bars represent the average of a technical replicate (n = 3) and error bars indicate the SD.(D) Real-time qRT-PCR analysis in differentiated FUS^WT^ iPSCs (day 12) transfected with anti-FUS or control siRNAs. Histogram bars represent the expression relative to the siRNA control (average of three independent experiments). Error bars indicate the SD (Student\'s t test; paired; two tails; ^∗^p \< 0.05; ^∗∗^p \< 0.01; where not indicated p \> 0.05). See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

miR-375 has been recently described as a protective miRNA in MNs ([@bib8]). Consistent with previous observations ([@bib8]), miR-375 was highly upregulated in MNs compared with undifferentiated iPSCs ([Figure 4](#fig4){ref-type="fig"}C). To gain insights into the mechanisms underlying miR-375 downregulation in FUS^P525L^ MNs we transfected differentiating FUS^WT^ iPSCs with small interfering RNAs (siRNAs) targeting *FUS* and analyzed gene expression at day 12 of differentiation. In these conditions, *FUS* levels were reduced to about 60% compared with scramble siRNA-transfected cells ([Figure 4](#fig4){ref-type="fig"}D). We have previously shown that FUS localization in the nucleus in homozygous FUS^P525L^ cells is reduced to 50% of its normal levels, due to partial delocalization in the cytoplasm ([@bib32]). Therefore, the decrease of FUS achieved by siRNA in WT cells is expected to reproduce possible loss of nuclear function effects of the mutation. FUS reduction did not affect differentiation, as assessed by *ISL1*, *CHAT*, and *TUJ1* marker analysis ([Figure 4](#fig4){ref-type="fig"}D). Levels of miR-375 were significantly reduced upon FUS knockdown ([Figure 4](#fig4){ref-type="fig"}D). Conversely, expression of selected genes among the most upregulated (*NNAT*, *TSPYL5*, and *TAF15*) or downregulated (*CRIM1* and *SLC17A8*) ones in FUS^P525L^ MNs was not affected by FUS knockdown ([Figure 4](#fig4){ref-type="fig"}D).

These results suggest that ALS mutations in the *FUS* gene might impair miR-375 production via a nuclear loss-of-function mechanism, while gain of toxic functions of the mutated protein might underlie the alteration of protein-coding genes expression.

miR-375 Target Genes in *FUS* Mutant MNs {#sec2.5}
----------------------------------------

To identify miR-375 targets in human MNs, we crossed mRNA expression data from the RNA-seq with predicted (TargetScan; [@bib2]) and previously validated targets (miRTarBase; [@bib12]). Eight mRNAs upregulated in FUS^P525L^ MNs were also miR-375 predicted targets ([Figure 5](#fig5){ref-type="fig"}A; [Table S3](#mmc3){ref-type="supplementary-material"}), including *ELAVL4* (also known as *HuD*), which had been previously validated as a *bona fide* miR-375 target ([@bib1]). The increased expression of *ELAVL4* and other predicted targets (*PHLDA1*, *EBF3*, *B3GAT2*) in mutant MNs was validated by real-time qPCR ([Figure 5](#fig5){ref-type="fig"}B). The *ELAVL4* gene encodes for a neuron-specific RNA-binding protein ([@bib10]). In mouse MNs, the transcript of the *NRN1* (*CPG15*) gene is among known targets of ELAVL4, which promotes *NRN1* mRNA accumulation by enhancing its stability ([@bib3]). In line with this, we detected increased levels of *NRN1* in FUS^P525L^ MNs ([Figure 5](#fig5){ref-type="fig"}B).Figure 5miR-375 Target Analysis(A) Venn diagram showing the relations between predicted miR-375 targets and mRNAs upregulated in FUS^P525L^ MNs, as resulting from the RNA-seq analysis.(B) Real-time qRT-PCR analysis in MNs at day 12 + 7. Expression levels in FUS^P525L^ and FUS^P525L^\#2 are shown as relative to their respective isogenic FUS^WT^ controls, set to a value of 1. Histogram bars represent the average of at least three independent experiments and error bars indicate the SD (Student\'s t test; paired; two tails; ^∗^p \< 0.05; ^∗∗∗^p \< 0.001; n.s., p \> 0.05).(C) Western blot analysis of p53 protein levels in FUS wild-type and mutant MNs at day 12 + 7. GAPDH is used as a housekeeping control.(D) Real-time qRT-PCR analysis of the expression of the indicated genes in differentiated FUS^P525L^ iPSCs transfected with miR-375 miRNA mimics. Expression levels are relative to mimics control (mimics-C)-transfected samples. Histogram bars represent the average of at least three independent experiments and error bars indicate the SD (Student\'s t test; paired; two tails; ^∗^p \< 0.05; ^∗∗∗^p \< 0.001; n.s., p \> 0.05).

We then noticed that the p53 gene (*TP53*) was a previously described target of miR-375 ([@bib35]). *TP53* mRNA was unchanged or slightly upregulated, respectively, in FUS^P525L^ and FUS^P525L^\#2 MNs ([Figure 5](#fig5){ref-type="fig"}B). In both lines, we detected an increase of p53 protein by western blot ([Figure 5](#fig5){ref-type="fig"}C). Among miR-375 targets, we noticed that *EBF3* and *PHLDA1* (also known as *TDAG51*) have been previously involved in the induction of apoptosis ([@bib18], [@bib48]).

To assess whether changes in target mRNA levels could be explained by differences in miRNA levels, we transfected synthetic miR-375 mimics in FUS^P525L^ differentiated cells. We observed a significant decrease of *ELAVL4* and *TP53* mRNA levels compared with control-transfected cells (mimics-C) ([Figure 5](#fig5){ref-type="fig"}D). Since levels of *EBF3* and *PHLDA1* were not decreased, we hypothesize that other mechanisms might contribute to their upregulation in FUS mutant cells.

Collectively, these findings suggest that dysregulation of miR-375 in *FUS* mutant MNs may have an impact on RNA metabolism and survival due to aberrant increase of ELAVL4 and p53, respectively.

Discussion {#sec3}
==========

In this study we report the whole-transcriptome profile of *in-vitro*-derived human MNs with WT or mutant (P525L) *FUS* background. Our analysis was performed on two pairs of isogenic lines generated by gene editing. We therefore provide significant information on the changes in the transcriptome of the neuronal subtype primarily affected by ALS and due solely to the specific, ALS-linked, FUS^P525L^ mutation. This represents a major advance beyond previous work, in which the transcriptome of mixed populations of progenitor cells (composed for the most part of non-MN cells and derived from non-isogenic *FUS* control/mutant iPSCs) was profiled by exon array ([@bib22]).

We found that numerous differentially expressed genes belong to functional categories related to the cell adhesion pathway. Interestingly, this correlates with transcriptome analysis of postmortem laser-capture microdissected MNs from ALS patients, genome-wide association studies on several neurological diseases and differential gene expression in *C9ORF72* mutant cells ([@bib5], [@bib6], [@bib19], [@bib28]). In the light of our findings, cell adhesion-related pathways might be considered as biomarkers and/or therapeutic targets in *FUS* ALS patients.

We also crossed our data with the transcriptome analysis from a recently reported murine model ([@bib43]). Among genes commonly upregulated in both species we noticed *TAF15*, which is mutated in some ALS patients ([@bib13]). TAF15 is a member of the FET family of RNA-binding proteins and is closely related to FUS. Similarly to FUS and TDP-43, upregulation of WT TAF15 causes neurodegeneration in *Drosophila* ([@bib13]). Notably, *TAF15* levels were slightly increased in FUS null mice ([@bib25], [@bib43]), but not in human MNs with reduced FUS levels ([Figure 4](#fig4){ref-type="fig"}D). This discrepancy might be explained by residual FUS protein in our RNAi experiment. A shift in TAF15 solubility and its localization into FUS-positive inclusions has been observed in frontotemporal lobar degeneration, but not in ALS ([@bib38]). Therefore, it remains unclear whether TAF15 upregulation in FUS mutant MNs contributes to ALS pathogenesis.

Changes in mRNA levels may be a direct consequence of the *FUS* mutation. Despite the fact that specific information on FUS-bound transcripts in human MNs is still missing, FUS CLIP-seq data from human brain cortex are available ([@bib31]). Our results suggest a possible direct effect of *FUS* mutations on those transcripts that are targeted by FUS on their 3′ UTR. Interestingly, levels of several transcripts were altered in the same direction in homozygous and heterozygous FUS^P525L^ MNs. The P525L mutation is inherited in an autosomal dominant way in ALS patients, and homozygous individuals have never been reported. Unexpectedly, in spinal cord tissue from heterozygous *FUS* ALS patients a near absence of nuclear FUS was observed in MNs, suggesting that both mutant and WT FUS can be sequestered within cytoplasmic inclusions ([@bib46]). As the nuclear fraction of FUS in homozygous and heterozygous P525L cells is, respectively, 80% and 50% ([@bib32]), the homozygous mutant could be regarded as representative of a more advanced stage of the disease. Mechanistically, toxic functions of mutant FUS might underlie the alteration of at least a subset of mRNAs, as suggested by knockdown experiments.

*FUS* mutations might also affect gene expression indirectly, for instance by altering miRNA levels. We found that miR-375 levels were consistently lower in MNs derived from two independent FUS^P525L^ lines. [@bib8] recently showed that miR-375 is enriched in human spinal MNs derived from embryonic stem cells. Interestingly, miR-375 overexpression protected MNs from DNA damage-induced apoptosis. Mechanistically, miR-375 may exert this function by targeting p53 ([@bib8], [@bib35]). We show here that p53 and other pro-apoptotic miR-375 predicted targets are upregulated in *FUS* mutant MNs. Notably, spinal MNs of ALS patients have been shown to display higher levels of p53 protein, which could be involved in apoptosis-mediated neuronal death ([@bib36], [@bib40]).

In FUS^P525L^ MNs we observed 40%--50% reduction in miR-375 levels. This is strikingly similar to the situation observed by [@bib8] in SMA MNs, in which miR-375 levels were reduced to 40%. Therefore, miR-375 dysregulation represents a common feature between two different MN diseases. While the molecular basis of miR-375 downregulation in SMA MNs remains currently unknown, we propose that ALS mutations causing FUS exclusion from the nucleus impair miR-375 production via a loss-of-function mechanism.

In addition to p53-induced apoptosis, miR-375 dysregulation might have an impact on other crucial pathways. Its decrease in FUS^P525L^ MNs is mirrored by an increase of its target ELAVL4, an RNA-binding protein playing multiple roles in neural development, function, and degeneration ([@bib10]). ELAVL4 regulates the stability and/or localization of several target transcripts. We propose that FUS, through the miR-375/ELAVL4 axis, is hierarchically at the top of a regulatory network with a broader role in the RNA metabolism of MNs.

In conclusion, transcriptome analysis of isogenic FUS^WT^ and FUS^P525L^ *in-vitro*-derived human MNs provided an insight on target genes and pathways altered by ALS mutations in the cell type primarily affected by the disease.

Experimental Procedures {#sec4}
=======================

Maintenance and Differentiation of Human iPSCs {#sec4.1}
----------------------------------------------

Generation and maintenance of iPSC lines is described in [@bib32]. The MN differentiation protocol has been modified from [@bib21]. In brief, cells were differentiated in N2B27 medium supplemented with 1 μM all-*trans* retinoic acid (Sigma-Aldrich) and 1 μM SAG (Merck Millipore) for 12 days in the presence of 10 μM SB431542 and 100 nM LDN-193189 (both from Miltenyi Biotec) from day 0 to 6, and 5 μM DAPT and 4 μM SU-5402 (both from Sigma-Aldrich) from day 6 to 12. Cells were sorted at day 12 using a FACSAria III (BD Biosciences) and re-plated on poly-L-ornithine-coated dishes and laminin- coated dishes (both from Sigma-Aldrich) in Neural Medium. The *Hb9*:GFP reporter was stably integrated in the *AAVS1* locus, as described previously ([@bib47]).

RNA and Protein Analysis {#sec4.2}
------------------------

Total RNA, extracted with the Quick-RNA MiniPrep (Zymo Research) and retrotranscribed with SuperScript VILO (Thermo Fisher Scientific) or miScript II RT (QIAGEN), was analyzed by real-time qRT-PCR with SYBR Green PowerUP (Thermo Fisher Scientific) or SYBR Green PCR Master Mix (QIAGEN). For miRNAs 384 array, RNA retrotranscribed using the TaqMan MicroRNA RT Kit was analyzed using the TaqMan Human MicroRNA Array A (Thermo Fisher Scientific). Primers sequences are reported in [Table S4](#mmc1){ref-type="supplementary-material"}. Western blot analysis was carried out using anti-p53 (fl-393; Santa Cruz) and anti-GAPDH (sc-32233) antibodies.

RNA-Seq and Bioinformatics Analysis {#sec4.3}
-----------------------------------

Total RNA was sequenced on an Illumina HiSeq 2500 sequencing system using a TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero treatment (Illumina) or the TruSeq Small RNA Library (Illumina) at the Institute of Applied Genomics (Udine, Italy). An average of about 21 million 125 base pairs long paired-end reads or 17 million 50 base pairs long single-end reads were produced for each sample for RNA-seq or small RNA-seq, respectively. Bioinformatics analysis is described in detail in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

RNA-seq raw data have been deposited at the GEO (GEO: [GSE94888](ncbi-geo:GSE94888){#intref0010}).

Immunostaining {#sec4.4}
--------------

Immunostaining was performed with anti-Islet-1/2 (1:50, 39.4D5; DSHB) primary antibody and anti-mouse Alexa Fluor 488 (1:250, Thermo Fisher Scientific) goat secondary antibody. Images were acquired with an inverted iX73 microscope (Olympus).

FUS Knockdown and miRNA Mimics Transfection {#sec4.5}
-------------------------------------------

Differentiating FUS^WT^ iPSCs were transfected at 8 and 10 days with 40 nM anti-FUS siRNAs (SI00070518, QIAGEN) or scramble control siRNAs (1027281, QIAGEN). FUS^P525L^ iPSCs, induced to differentiate into MNs for 14 days and seeded on Matrigel-coated plates, were transfected after 48 hr with 10 nM mirVana miRNA mimics (miR-375-3p MIMAT0000728; Negative Control No. 1 Cat. 4464058; Thermo Fisher Scientific). RNA was collected for real-time qRT-PCR analysis after 48 hr.
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====================
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